Back to cases

Diabetes · Diabetes mellitus

吴*华· 68 male

Country
China
Treatment start
2023

Anamnesis

Wú*Huá, male, age 68, diabetes for 20+ years, insulin therapy with unsatisfactory glycemic control. HbA1c 6.8%, fasting blood glucose 7.8.

Treatment plan

In 2023 — umbilical cord mesenchymal stem cells (UC-MSC) 5U IV, once monthly, 3 consecutive administrations.

Schema5U IV monthly × 3 cycles
Therapy
UC-MSC (umbilical cord MSC)
Delivery route
Intravenous (IV)

Outcome

After one course of stem cell infusion, follow-up tests showed fasting blood glucose and HbA1c within normal range. Appetite improved, immune function enhanced, insulin dose effectively reduced. Two-year follow-up confirmed stable blood glucose control.

Physician conclusion

No adverse reactions observed. Stem cell infusion increases islet β-cell count, effectively regulates glucose and insulin levels, improves islet function, and controls insulin resistance.

Discuss your case

Share your diagnosis and history — the academic board responds within 24 hours with a preliminary assessment and protocol outline.

Get a consultation

We use cookies and analytics services to improve the website experience. Privacy Policy